Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 25, 2025 • 11:01 PM ET

Date/Time Source News Release
04/14/2025 08:00 AM EDT GlobeNewswire Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
04/02/2025 04:01 PM EDT GlobeNewswire Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/05/2025 04:01 PM EST GlobeNewswire Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
03/04/2025 04:01 PM EST GlobeNewswire Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
02/14/2025 04:01 PM EST GlobeNewswire Fate Therapeutics to Present at Upcoming Investor Conferences
02/04/2025 04:01 PM EST GlobeNewswire Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/03/2025 04:01 PM EST GlobeNewswire Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/09/2024 04:01 PM EST GlobeNewswire Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
12/03/2024 04:01 PM EST GlobeNewswire Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
11/29/2024 01:05 PM EST GlobeNewswire Fate Therapeutics Announces Leadership Transition
Page

Additional News

As of April 25, 2025 • 11:01 PM ET

Date/Time Source News Release
04/15/2025 10:42 AM EDT Zacks Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
04/14/2025 11:34 AM EDT SeekingAlpha Fate Therapeutics gets RMAT status from FDA for Lupus treatment
04/04/2025 11:30 AM EDT Zacks Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?
03/07/2025 09:21 AM EST Baystreet From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025
03/06/2025 09:04 AM EST Zacks FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
03/05/2025 05:10 PM EST Zacks Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
03/05/2025 04:51 PM EST SeekingAlpha Fate Therapeutics GAAP EPS of -$0.44 misses by $0.02, revenue of $1.86M beats by $0.29M
03/03/2025 06:00 AM EST US Earnings Reports Expected US Company Earnings on Monday, March 3rd, 2025
03/03/2025 04:30 AM EST US Earnings Reports Expected earnings - Fate Therapeutics Inc.
02/26/2025 10:52 AM EST SeekingAlpha Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.